TSAP (Boltz-2)TSAP (AI-QSAR)
Immuno-oncology

MAP4K1 activity model

MAP4K1 (HPK1) is a serine/threonine kinase that dampens T-cell receptor signaling. Blocking it strengthens T-cell responses, which makes it an immuno-oncology target.

A model trained on measured activity data for MAP4K1 (Immuno-oncology). Give it compounds and it predicts their Ki against MAP4K1, so you can rank candidates by it.

Predict with this model

Model card
UniProt
Q92918
Reference structure
PDB 8CIJ, ligand USF
Training data
TSAP (Boltz-2): 120 compounds, KiTSAP (AI-QSAR): 120 compounds, Ki
Validation
Predicted and measured values are compared on compounds held out of training.
Cost
From 100 cr, quoted before you submit
Model version
TSAP (Boltz-2): TSAP pipeline v2.2TSAP (AI-QSAR): Ridge regression on docking features
MAP4K1 receptor structure (PDB 8CIJ) with the ligand USF in the binding pocket

Validation results

Predicted and measured values compared on compounds held out of training. RMSE is in log units (pIC50 and similar).

TSAP (Boltz-2)

Pearson r

0.88

R²

0.72

RMSE (log units)

0.60

Holdout compounds

30

TSAP (AI-QSAR)

Pearson r

0.84

Square root of RSQ

RSQ

0.70

Holdout compounds

30

How to use it

  1. Under Predict with this model, press TSAP (Boltz-2) or TSAP (AI-QSAR). The wizard of the workflow you pressed opens with the MAP4K1 model already selected.

  2. Upload the SMILES of the compounds to predict as a .smi, .csv or .txt file.

  3. Check the estimated credits and time, then submit.

  4. The result is a table of compounds ranked by predicted Ki.

Limitations

  • Predictions can be less accurate for compounds whose structures differ a lot from the training data.
  • Validation used only about 30 compounds, so performance on new compounds can differ from these metrics.
  • Predictions do not replace experiments. Use them to decide what to synthesize and measure first.